Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma Research Letter

  


Authors: Soumerai, J. D.; Rosenthal, A.; Harkins, S.; Duffy, J.; Mecca, C.; Wang, Y.; Grewal, R. K.; El-Jawahri, A. R.; Liu, H.; Menard, C.; Dogan, A.; Yang, L.; Rimsza, L. M.; Bantilan, K.; Martin, H.; Lei, M.; Mohr, S.; Kurilovich, A.; Kudryashova, O.; Postovalova, E.; Nardi, V.; Abramson, J. S.; Chiarle, R.; Zelenetz, A. D.; Louissaint, A. Jr
Title: Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
Keywords: clinical article; human tissue; human cell; genetics; nonhuman; letter; animal cell; mouse; animal tissue; protein kinase inhibitor; lung neoplasms; cohort analysis; pathology; protein kinase inhibitors; lung tumor; b cell lymphoma; lymphoma, b-cell; xenograft; tumor recurrence; clinical evaluation; therapy effect; anaplastic lymphoma kinase; crizotinib; humans; human; alectinib; lorlatinib; drug vehicle; daratumumab plus hyaluronidase; alk-positive anaplastic large cell lymphoma; anaplastic lymphoma kinase positive large b cell lymphoma
Journal Title: Blood
Volume: 140
Issue: 16
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2022-10-20
Start Page: 1822
End Page: 1826
Language: English
DOI: 10.1182/blood.2022015443
PUBMED: 35802834
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139871435&doi=10.1182%2fblood.2022015443&partnerID=40&md5=2135aa9e0a8bbc9317cc116330d67526
Notes: Letter -- Export Date: 1 November 2022 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Ravinder K Grewal
    82 Grewal
  2. Andrew D Zelenetz
    767 Zelenetz
  3. Ahmet Dogan
    454 Dogan
  4. Kurt Bantilan
    25 Bantilan
Related MSK Work